Design Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Design Therapeutics, Inc. on June 13, 2024. The record date for the meeting was April 18, 2024, with 56,495,039 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Pratik Shah, Ph.D., was elected as a Class III Director to serve until the 2027 Annual Meeting.
- Votes For: 42,785,096
- Votes Withheld: 3,511,039
- Broker Non-Votes: 7,688,435
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024.
- Votes For: 53,981,806
- Votes Against: 2,764
- Abstentions: 2
- Broker Non-Votes: Not applicable
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Pratik Shah, Ph.D., was re-elected to the Board of Directors with approximately 76% of votes cast in favor (excluding broker non-votes).
- Ernst & Young LLP was overwhelmingly ratified as the independent auditor with over 99% of votes cast in favor.
- There were 7,688,435 broker non-votes on the director election, indicating a significant portion of shares held in street name where brokers lacked discretionary voting power.
- The company is classified as an emerging growth company.